

5. Joshi S, Sciacca RR, Solanki DR, Young WL, Mathru MM. A prospective evaluation of clinical tests for placement of laryngeal mask airways. *Anesthesiology* 1998; **89**: 1141–6
6. Payne J. The use of the fiberoptic laryngoscope to confirm the position of the laryngeal mask. *Anaesthesia* 1989; **44**: 865
7. Van Zundert AAJ, Kumar CM, Van Zundert TCRV. Malpositioning of supraglottic airway devices: preventive and corrective strategies. *Br J Anaesth* 2016; **116**: 579–82

doi: 10.1093/bja/aex010

## Preoxygenation using the Optiflow™ system

K. S. Ang\*, A. Green, K. K. Ramaswamy and C. Frerk

Northampton, United Kingdom

\*E-mail: kingsin\_ang@yahoo.com

Editor—The use of transnasal humidified oxygen delivery system (Optiflow™, Fisher and Paykel Healthcare Limited, Auckland, New Zealand) has been described to provide preoxygenation and to extend the apnoea time of patients with difficult airways in the THRIVE study.<sup>1</sup> The purpose of preoxygenation is to increase alveolar oxygen fraction,<sup>2</sup> which is inferred by the measurement of end tidal oxygen concentration (EtO<sub>2</sub>). We conducted an observational pilot study to evaluate the performance of the Optiflow™ system in preoxygenating patients.

The study was approved by London–West London Research Ethics Committee (Ref: 15/LO/1895). Healthy volunteers who gave

written informed consent were recruited. Volunteers sat semi-recumbent on an operating theatre trolley. Optiflow™ nasal cannulae were fitted and the volunteers were instructed to breathe normally through the nose, with the mouth closed. At time zero, the oxygen supply was turned on at 70 l min<sup>-1</sup>. After 30 s, oxygen was switched off and the volunteers were asked to breathe out into a mouthpiece connected to a GE Healthcare gas analyser. Once EtO<sub>2</sub> returned to baseline, the test was repeated using five further predetermined times: 60, 90, 120, 150 and 180 s. Each volunteer was asked to grade the level of discomfort experienced with the transnasal high flow oxygen using a visual analogue score (VAS).




Fig 1 xxx

Twenty-one healthy volunteers aged 23–59 yr were enrolled into the study. One volunteer withdrew midway after experiencing discomfort with the Optiflow™ system, leaving 20 to complete the protocol. Baseline EtO<sub>2</sub> was between 14–17%. EtO<sub>2</sub> rose quickly, but only 10 out of 20 volunteers achieved an EtO<sub>2</sub> of 90% within three min. The median [IQR (range)] EtO<sub>2</sub> for each time interval (30, 60, 90, 120, 150 and 180 s) was 72% [66–79% (45–82%)], 79% [71–86% (65–89%)], 84% [77–88% (64–91%)], 87% [80–91% (72–93%)], 88% [83–90% (75–94%)] and 86% [84–90% (78–92%)] respectively. Four out of 20 volunteers recorded a VAS for discomfort of five or six.

High flow humidified nasal oxygen has been used in a variety of settings, including anaesthesia,<sup>3</sup> intensive care<sup>4,5</sup> and emergency departments.<sup>6</sup> It flushes the anatomical dead space and provides low-grade positive pressure depending on flow and degree of mouth opening.<sup>4,6</sup> There has been recent focus regarding the role of Optiflow™ in apnoeic oxygenation during intubation, particularly in hypoxaemic patients,<sup>7,8</sup> morbidly obese patients<sup>9</sup> and patients with potentially difficult airways.<sup>1</sup>

Our study demonstrated that the Optiflow™ system increased EtO<sub>2</sub> rapidly, however the variability in the extent of denitrogenation suggests that it might not be a reliable alternative to face mask ventilation in preoxygenating patients. Optiflow™ has been described as "well tolerated",<sup>5,6</sup> but four out of 20 volunteers gave a VAS for discomfort of  $\geq 5$ . Delivering nasal oxygen at induction of anaesthesia has been recommended in national guidelines,<sup>10,11</sup> this recommendation remains valid as there are studies demonstrating its role in preventing desaturation and maintaining arterial oxygen content during apnoea.<sup>1,8,9</sup>

We did not investigate other patterns of breathing such as breathing with the mouth open or taking vital capacity breaths. We considered measuring transcutaneous oxygen concentration or arterial oxygen concentration, but these techniques do not measure the size of the alveolar oxygen reservoir. Our findings could inform future studies into transnasal high flow oxygen therapy.

## Declaration of interest

Fisher and Paykel Healthcare Limited loaned the Optiflow™ system to Northampton General Hospital but was not involved in any part of study design/planning, or in the preparation of this letter.

## Acknowledgements

We would like to acknowledge our collaborators, Michelle Spinks, Julie Wilson, Jenny Spimpolo and Farhad Alexander-Sefre, for their help in developing the project.

## References

1. Patel A, Nouraei SAR. Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE): a physiological method of increasing apnoea time in patients with difficult airways. *Anaesthesia* 2015; **70**: 323–9
2. Bhatia PK, Bhandari SC, Tulsiani KL, Kumar Y. End-tidal oxygraphy and safe duration of apnoea in young adults and elderly patients. *Anaesthesia* 1997; **52**: 175–8
3. Badiger S, John M, Fearnley RA, Ahmad I. Optimising oxygenation and intubation conditions during awake fibre-optic intubation using a high-flow nasal oxygen delivery system. *Br J Anaesth* 2015; **115**: 629–32
4. Parke RL, McGuinness SP, Eccleston M. A preliminary randomized controlled trial to assess effectiveness of nasal high-flow oxygen in intensive care patients. *Respir Care* 2011; **56**: 265–70
5. Sztrymf B, Messika J, Bertrand F, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. *Intensive Care Med* 2011; **37**: 1780–6
6. Lenglet H, Sztrymf B, Leroy C, Brun P, Dreyfuss D, Ricard J-D. Humidified high flow nasal oxygen during respiratory failure in the emergency department: a feasibility and efficacy study. *Respir Care* 2012; **57**: 1873–8
7. Vourc'h M, Asfar P, Volteau C, et al. High-flow nasal cannula oxygen during endotracheal intubation in hypoxaemic patients: a randomised controlled clinical trial. *Intensive Care Med* 2015; **41**: 1538–48
8. Miguel-Montanes R, Hajage D, Messika J, et al. Use of high-flow nasal cannula oxygen therapy to prevent desaturation during tracheal intubation of intensive care patients with mild to moderate hypoxaemia. *Crit Care Med* 2015; **43**: 574–83
9. Heinrich S, Horbach T, Stubner B, Prottengeier J, Irouschek A, Schmidt J. Benefits of heated and humidified high flow nasal oxygen for preoxygenation in morbidly obese patients undergoing bariatric surgery: A randomised controlled study. *J Obes Bariatrics* 2014; **1**: 7–13
10. Frerk C, Mitchell VS, McNarry AF, et al. Difficult Airway Society 2015 guidelines for management of unanticipated difficult intubation in adults. *Br J Anaesth* 2015; **115**: 827–48
11. Mushambi MC, Kinsella SM, Popat M, et al. Obstetric Anaesthetists' Association and Difficult Airway Society guidelines for management of difficult and failed tracheal intubation in obstetrics. *Anaesthesia* 2015; **70**: 1286–306

doi: 10.1093/bja/aex016